Innoviva to Participate in the UBS Global Healthcare Conference
Innoviva (NASDAQ: INVA), a diversified holding company with a core royalties portfolio and a critical care and infectious disease platform, announced its management's participation in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA.
The event will take place on Wednesday, November 13, 2024, at 10:15 a.m. Pacific Time. A live webcast can be accessed under the 'Events & Presentations' section of Innoviva's Investor Relations website. The webcast will be available for replay for 90 days after the event.
Innoviva (NASDAQ: INVA), una società di holding diversificata con un portafoglio principale di royalties e una piattaforma specializzata in cure critiche e malattie infettive, ha annunciato la partecipazione del proprio management a una chiacchierata informale durante la Conferenza Globale sulla Sanità UBS a Ranch Palos Verdes, CA.
L'evento si svolgerà mercoledì 13 novembre 2024 alle 10:15 ora del Pacifico. È possibile accedere a una diretta dell'evento nella sezione 'Eventi e Presentazioni' del sito web delle Relazioni con gli Investitori di Innoviva. La trasmissione sarà disponibile per la visione in differita per 90 giorni dopo l'evento.
Innoviva (NASDAQ: INVA), una empresa de holding diversificada con un portafolio de regalías central y una plataforma de cuidados críticos y enfermedades infecciosas, anunció la participación de su dirección en una charla informal en la Conferencia Global de Salud UBS en Ranch Palos Verdes, CA.
El evento tendrá lugar el miércoles 13 de noviembre de 2024 a las 10:15 a.m. hora del Pacífico. Se podrá acceder a una transmisión en vivo en la sección 'Eventos y Presentaciones' del sitio web de Relaciones con Inversores de Innoviva. La transmisión estará disponible para su repetición durante 90 días después del evento.
Innoviva (NASDAQ: INVA)는 핵심 로열티 포트폴리오와 중환자 진료 및 감염병 플랫폼을 갖춘 다각화된 지주 회사로, CA의 Ranch Palos Verdes에서 열리는 UBS 글로벌 헬스케어 컨퍼런스에서 경영진이 열린 대화에 참여할 것이라고 발표했습니다.
이 행사는 2024년 11월 13일 수요일 오전 10:15 태평양 시간에 진행됩니다. Innoviva 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션에서 생중계를 이용할 수 있습니다. 생중계는 행사 후 90일 동안 다시 볼 수 있습니다.
Innoviva (NASDAQ: INVA), une société holding diversifiée disposant d'un portefeuille de redevances central et d'une plateforme de soins critiques et de maladies infectieuses, a annoncé la participation de sa direction à une discussion informelle lors de la Conférence Mondiale sur la Santé UBS à Ranch Palos Verdes, Californie.
L'événement aura lieu le mercredi 13 novembre 2024 à 10h15 heure du Pacifique. Un webcast en direct sera accessible dans la section 'Événements et présentations' du site web des Relations Investisseurs d'Innoviva. Le webcast sera disponible en replay pendant 90 jours après l'événement.
Innoviva (NASDAQ: INVA), ein diversifiziertes Holdingunternehmen mit einem zentralen Lizenzportfolio sowie einer Plattform für kritische Pflege und Infektionskrankheiten, gab die Teilnahme seines Managements an einem informellen Gespräch auf der UBS Global Healthcare Conference in Ranch Palos Verdes, Kalifornien, bekannt.
Die Veranstaltung findet am Mittwoch, den 13. November 2024 um 10:15 Uhr Pazifischer Zeit statt. Ein Livestream kann im Bereich 'Veranstaltungen & Präsentationen' der Investor Relations-Website von Innoviva aufgerufen werden. Der Livestream wird 90 Tage nach der Veranstaltung als Wiederholung verfügbar sein.
- None.
- None.
A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.
About Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112829799/en/
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
FAQ
When will Innoviva participate in the UBS Global Healthcare Conference?
How can I access the live webcast of Innoviva's fireside chat at the UBS Global Healthcare Conference?
What is the stock symbol for Innoviva?
How long will the webcast of Innoviva's fireside chat be available for replay?
What time is Innoviva's fireside chat at the UBS Global Healthcare Conference?
